With the development of S1P-205, the company is taking steps to address desire disparity between partners and dispelling the myth than men don’t have problems with desire.
S1 Biopharma chief medical officer Robert E. Pyke said,"PDE-5 inhibitor therapies are only half the story, and we hope to address the other half with S1P-205, helping men and their partners to have more fulfilling relationships."
S1 Biopharma CEO Nicolas G. Sitchon said, "S1P-205 and Lorexys, our drug for female HSDD, are perfect for this dual treatment approach."